Aadi Bioscience, Inc. (AADI) |
|
7.25 -0.04 (-0.55%)
|
03-24 16:00 |
|
Open: |
7.22 |
Pre. Close: |
7.29 |
|
High:
|
7.29 |
Low:
|
7.09 |
|
Volume:
|
116,879 |
Market Cap:
|
177(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:42 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 11.65  One year: 13.8 |
| Support: |
Support1: 7 Support2: 5.82 |
| Resistance: |
Resistance1: 9.97 Resistance2: 11.82 |
| Pivot: |
7.92 |
| Moving Average: |
MA(5): 7.4 MA(20): 8.57
MA(100): 11.85 MA(250): 13.08 |
| MACD: |
MACD(12,26): -1.1  Signal(9): -1.1 |
| Stochastic oscillator: |
%K(14,3): 7.9 %D(3): 10.2 |
| RSI: |
RSI(14): 26 |
| 52-week: |
High: 18.46 Low: 7 |
| Average Vol(K): |
3-Month: 124 (K) 10-Days: 160 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AADI ] has closed above bottom band by 20.3%. Bollinger Bands are 35.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.3 - 7.34 |
7.34 - 7.37 |
|
Low:
|
7.01 - 7.04 |
7.04 - 7.08 |
|
Close:
|
7.19 - 7.25 |
7.25 - 7.3 |
|
Company Description |
|
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. |
Headline News |
Thu, 23 Mar 2023
100+ Active Companies working to Develop 100+ Pipeline ... - Digital Journal
Tue, 21 Mar 2023
Aadi Bioscience (AADI) to Release Earnings on Tuesday - MarketBeat
Thu, 16 Mar 2023
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates - Nasdaq
Thu, 16 Mar 2023
Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update - MarketBeat
Fri, 03 Mar 2023
Aadi Bioscience Announces Leadership Transition - PR Newswire
Tue, 28 Feb 2023
Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
24 (M) |
| Shares Float |
16 (M) |
|
% Held by Insiders
|
11.6 (%) |
|
% Held by Institutions
|
63.4 (%) |
|
Shares Short
|
1,080 (K) |
|
Shares Short P.Month
|
1,180 (K) |
Stock Financials |
|
EPS
|
-8.9 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
7.23 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-540.9 |
|
Return on Assets (ttm)
|
-20.5 |
|
Return on Equity (ttm)
|
-39.2 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
-0.77 |
|
Sales Per Share
|
0.45 |
|
EBITDA (p.s.)
|
-2.43 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-51 (M) |
|
Levered Free Cash Flow
|
-30 (M) |
Stock Valuations |
|
PE Ratio
|
-0.82 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
1 |
|
Price to Sales
|
16.09 |
|
Price to Cash Flow
|
-3.49 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
